Emily Salmini

[Nature Biomedical Engineering] Given the unique abilities of macrophages to cross the blood–brain barrier and exert their phagocytic function on tumour cells, researchers genetically engineered macrophages that express a CAR targeting mesothelin.

[Blood] Researchers tested a broad array of strategies to enhance CD4CAR-T cell efficacy, including CRISPR-Cas9-mediated gene editing of immune checkpoint and HIV-associated genes, single and pooled competitive infusions of engineered CAR-T cells, and exogenous antigen boosting.

[Cell Stem Cell] Scientists developed a PSC-derived induced natural killer lineage-committed progenitor cell therapy (iNKP) in leukemia models. They generated abundant iNKP cells via an organoid culture system.

[Science Advances] Investigators developed CAR T cells targeting KRASG12V/HLA-A*02:01 using phage antibody display to identify high-affinity single-chain variable fragments.

[Journal for Immunotherapy of Cancer] In natural killer (NK)-competent humanized mice, adoptively transferred, unselected, unmodified NK cells slowed tumor growth in a dose-dependent manner, but NK cells selected to avoid HLA I-driven inhibition were the most competent effectors for PDAC control.

[Experimental & Molecular Medicine] Microbial metabolites, such as short-chain fatty acids, indole metabolites and bile acids, can exert specific regulatory effects on the various components of the immune system, such as barrier epithelial cells and immune cells, including dendritic cells, macrophages, T cells, B cells, innate lymphoid cells, and mast cells.